PMID- 24172099
OWN - NLM
STAT- MEDLINE
DCOM- 20140701
LR  - 20181030
IS  - 1525-1438 (Electronic)
IS  - 1048-891X (Linking)
VI  - 23
IP  - 9
DP  - 2013 Nov
TI  - Treatment outcomes in completely resected stage I to stage IV uterine 
      carcinosarcoma with rhabdomyosarcoma differentiation.
PG  - 1635-41
LID - 10.1097/IGC.0000000000000001 [doi]
AB  - OBJECTIVE: To evaluate overall survival (OS) and progression-free survival (PFS) 
      after adjuvant therapy in stage I to stage IV uterine carcinosarcoma with 
      rhabdomyosarcoma differentiation. METHODS: Memorial Sloan-Kettering Cancer Center 
      medical records from 1990 to 2012 were reviewed. Patients who received 
      chemotherapy with or without radiation therapy (RT), or RT alone, for completely 
      resected stage I to stage IV uterine carcinosarcoma with rhabdomyosarcoma 
      differentiation were included. RESULTS: Of 53 patients, International Federation 
      of Gynecology and Obstetrics stage distribution was as follows: I, 13 (24.5%); 
      II, 8 (15.1%); III, 13 (24.5%); and IV, 19 (35.9%). Forty-one (77.4%) of 53 
      patients received adjuvant chemotherapy, and 34% of the patients who received 
      chemotherapy also received pelvic RT or intravaginal brachytherapy (IVRT). Twelve 
      (22.6%) of the 53 patients received only pelvic RT with/without IVRT. 
      Paclitaxel-carboplatin was the most commonly used adjuvant chemotherapy 
      treatment. The median PFS for the entire cohort was 13.4 months (95% confidence 
      interval [CI], 10.5-17.0). The median OS for the entire cohort was 23.0 months 
      (95% CI, 16.9-34.3). The median PFS periods by stage were 15.9 months for stages 
      I/II versus 11.2 months for stages III/IV (P = 0.012). Median OS was not reached 
      in the early-stage cohort. The median OS for the late-stage cohort was 20.9 
      months (P = 0.004). The median PFS periods by treatment were 10.4 months for 
      pelvic RT with/without IVRT group versus 13.1 months for chemotherapy 
      with/without pelvic RT with/without IVRT group (P = 0.498). The median OS periods 
      by treatment were 23.6 months for chemotherapy with/without pelvic RT 
      with/without IVRT group versus 16.9 months for pelvic RT with/without IVRT group 
      (P = 0.501). CONCLUSION: The results suggest that chemotherapy alone or in 
      combination with RT is associated with longer PFS and OS compared to RT alone. 
      Only the stage of disease significantly affected PFS and OS.
FAU - Makker, Vicky
AU  - Makker V
AD  - *Gynecologic Medical Oncology Service, Department of Medicine, Memorial 
      Sloan-Kettering Cancer Center; daggerDepartment of Medicine, Weill Cornell Medical 
      College; double daggerDepartment of Epidemiology and Biostatistics, and  section signDepartment of 
      Gynecologic Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY.
FAU - Kravetz, Sara J
AU  - Kravetz SJ
FAU - Gallagher, Jacqueline
AU  - Gallagher J
FAU - Orodel, Oana-Paula
AU  - Orodel OP
FAU - Zhou, Qin
AU  - Zhou Q
FAU - Iasonos, Alexia
AU  - Iasonos A
FAU - DeLair, Deborah
AU  - DeLair D
FAU - Aghajanian, Carol
AU  - Aghajanian C
FAU - Hensley, Martee L
AU  - Hensley ML
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Gynecol Cancer
JT  - International journal of gynecological cancer : official journal of the 
      International Gynecological Cancer Society
JID - 9111626
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinosarcoma/mortality/pathology/radiotherapy/*surgery
MH  - Cell Transdifferentiation
MH  - Female
MH  - Humans
MH  - Hysterectomy/methods
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Radiotherapy, Adjuvant/adverse effects
MH  - Rhabdomyosarcoma/mortality/pathology/radiotherapy/*surgery
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Uterine Neoplasms/mortality/pathology/radiotherapy/*surgery
EDAT- 2013/11/01 06:00
MHDA- 2014/07/02 06:00
CRDT- 2013/11/01 06:00
PHST- 2013/11/01 06:00 [entrez]
PHST- 2013/11/01 06:00 [pubmed]
PHST- 2014/07/02 06:00 [medline]
AID - 00009577-201311000-00015 [pii]
AID - 10.1097/IGC.0000000000000001 [doi]
PST - ppublish
SO  - Int J Gynecol Cancer. 2013 Nov;23(9):1635-41. doi: 10.1097/IGC.0000000000000001.